Moderna Inc. is turning to the courts in its ongoing intellectual property (IP) dispute with pharmaceutical rivals Pfizer and BioNTech, seeking a federal judge’s approval to access a set of communications and documents that may be crucial to its case. The documents in question are in the possession of a biochemist at the University of Pennsylvania, believed to contain key information potentially related to the patent quarrel surrounding a COVID-19 vaccine.
In recent litigation moves, Moderna requested the court to compel the biochemist to submit these materials for review. Since the biochemist technically falls outside the realm of the commenced legal proceedings between the biotech companies, Moderna had no authority to make this request independently, thus seeking judicial intervention.
Pfizer and BioNTech have yet to comment on the matter. Given the escalating patent dispute, this case serves as a reminder of the ongoing challenges and legal complexities surrounding pharmaceutical innovation, especially in an era dominated by the drive to combat the COVID-19 pandemic.
For more detailed information on the issue, legal practitioners can refer to the coverage by Law360.